

Formulation Studies on Hibiscus Sabdariffa (HS) Aqueous Extract

Y.J. Oyeniyi^{1*}, F.B.O. Mojiminiyi²

¹Department of Pharmaceutics & Pharm. Microbiology, Faculty of Pharm. Sciences, Usmanu Danfodiyo University, Sokoto, Nigeria,

²Department of Physiology, Faculty of Basic Medical Sciences, College of Health Sciences, Usmanu Danfodiyo University, Sokoto, Nigeria

ABSTRACT

Background: Hibiscus sabdariffa L. family Malvaceae is a perennial herbaceous medicinal shrub widely cultivated for its proven anti-hypertensive property

Objectives: The focus of this investigation is to formulate the aqueous extract of HS as oral tablets for accurate dosing and to ease the administration of the aqueous extract.

Method: Five formulations of HS granules were prepared by wet granulation technique and thereafter the flow characteristics of the granules were assessed through, angle of repose, Hausner's ratio, density measurements, moisture content and compressibility index determinations. Heckel and Kawakita analyses were however employed to study HS granules compactability, while the United State Pharmacopeia 2012 (USP) quality control tests were used to investigate the tableting properties.

Result: There were significant differences ($p \leq 0.05$) in the values obtained for the granules flow, compaction and tableting properties. The ranking order was the same for the angle of repose and the Hausner's ratio; $HS2 \leq HS3 \leq HS4 \leq HS5 \leq HS1$, implying HS2 having the best desirable flow characteristics. All the formulations underwent significant volume reduction under applied pressure, of which the PY and PK values ranked $HS1 \leq HS2 \leq HS4 \leq HS5 \leq HS3$ and $HS4 \geq HS5 \geq HS2 \geq HS3 \geq HS1$ respectively. All formulations except HS1 passed the quality assessment tests. HS1 even though had the fastest onset of plastic deformation; it however had the least quantitative plasticity and this may be responsible for its poor friability.

Conclusion: All HS Formulations except HS1 investigated had excellent tableting properties that fell within the specifications of the United State Pharmacopeia. The high friability of HS1 may not be unconnected to its lack of binding agent and low plasticity even though it onset of plastic deformation was the fastest.

Keywords: Hibiscus sabdariffa; Plastic deformation; tableting; Heckel and Kawakita analyses.

INTRODUCTION

Hibiscus sabdariffa L. family Malvaceae (HS) is a perennial herbaceous shrub grown widely in India, west and east Africa for its importance in folk medicine. It is a tropical plant native to Asia countries but now widely grown in both tropical and subtropical countries for its leaf, fleshy calyx, seed and fiber [1, 2]. HS calyx is widely used in production of non-alcohol drink popularly called Sobo enjoyed by all and sundry, [3]. HS is probably one of the most beautiful flowers in the whole world

with long history of uses such as its fragrant flowers used in the production of deodorant spray, the young fresh leaves for production of salad, the fibers used as jute substitutes, while the fleshy red calyxes are used in the preparation of jellies, jams, teas and drink, [4, 5]. In traditional medicine, HS aqueous extract is used in treating hypertensive and stroke patients. Interestingly there exist extensive research reports confirming the hypotensive properties of HS aqueous extract in both laboratory animals and in human subjects [6, 7, 8]. Other therapeutic properties of HS reported include, antioxidant [9], hypocholesterolemic [10, 11],

Correspondence to: Y.J. Oyeniyi, Department of Pharmaceutics & Pharm. Microbiology, Faculty of Pharm. Sciences, Usmanu Danfodiyo University, Sokoto1, Nigeria, Tel no: 2348033472945; E-mail: drdeyinkaoyeniyi@gmail.com

Received: 02-Jan-2023, Manuscript No. EOED-23-12192 **Editor assigned:** 04-Jan-2023, PreQC No.EOED-23-12192; (PQ); **Reviewed:** 18-Jan-2023, QC No.EOED-23-12192 **Revised:** 25-Jan-2023, Manuscript No. EOED-23-12192 (R); **Published:** 02-Feb-2023, DOI: 10.35248/2329-6631.23.12.186

Citation: Oyeniyi YJ., Mojiminiyi FBO. (2023) Formulation Studies on Hibiscus Sabdariffa (HS) Aqueous Extract. J Develop Drugs, 12:186.

Copyright: © 2023 Y.J. Oyeniyi. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

anti-obesity [12], insulin resistance reduction, skin cancer chemo preventive [13], diuretic [14], antimicrobial, and cytotoxic properties [15]. Phytochemical screening revealed that HS calyx as good source of carbohydrate, dietary fiber, protein, vitamins, minerals and bioactive compounds (flavonoids mainly anthocyanins, phytosterols, polyphenols, cardiac glycosides, saponins, alkaloids and organic acids, including citric acid, hydroxycitric acid, hibiscus acid, malic and tartaric acids), [16,17,18,19]. The Anthocyanin content is said to be responsible for improving the function of blood vessels and also strengthens protein collagen, [20]. There are several reports of HS aqueous extract significantly decreasing both the systolic and diastolic blood pressure in human subjects at a dose of 15mg/kg/day [21, 22, 23, 24,25, 26].

The therapeutic index of the extract is high with low degree of toxicity as reported LD50 ranged between 2,000 to 5,000mg/kg/day) [27]

This present investigation is devoted to developing HS aqueous extract into oral tablets thus ensuring accurate dosing, patients' compliance as a result of ease of administration of HS extract.

METHODS

Extraction

The extraction protocol adopted in this study was a modified version described by Kunle et al., 2002. The fresh red calyces of HS were harvested from the botanical garden of the department of pharmacognosy and drug development, Faculty of Pharmaceutical Sciences Usmanu Danfodiyo University Sokoto. The identification and voucher numbering were carried out by the department of biological sciences, Usmanu Danfodiyo University Sokoto. The calyces were thereafter air dried and size reduced into fine powder from which about 500g were measured and suspended in 2.7 L of hot water (50 OC) maintained under constant agitation with the aid of a magnetic stirrer for about 18 Hrs and thereafter filtered to obtained a red colored extract which was evaporated into a jelly mass using an hot air oven (Gallenkamp, Model OV-335, Vindon Scientific Ltd, UK), maintained at 60 OC, [28, 29].

Production of HS granules

HS granules were produced using the wet granulation technique according to table 1. Wet granulation technique (WGT) is a combination of series of sequential steps commencing with the weighing and mixing of both the API (HS) and the diluents. Since our API is in semi-solid state; require quantities of the diluent was weighed directly into a known quantity of HS jelly, mixed thoroughly using a rotary mixer (VM-5 V-shaped blender, Tokujin, Japan), and thereafter screened through sieve mesh size 1500. The wet granules were collected into a clean stainless steel tray, spread out evenly and thereafter dried using hot air operating at 45 OC for about 2hr. The dried granules were rescreened, weighed and kept in airtight container until needed, [30, 31, and 32].

Table 1: Batch formulation of HS tablets

Materials (Mg/Tab.)	HS1	HS2	HS3	HS4	HS5
API	275.0	275.0	275.0	275.0	275.0
MCS	217.0	144.5	144.5	Nil	Nil
Starch	Nil	Nil	Nil	144.5	Nil
Lactose	Nil	Nil	Nil	Nil	144.5
Gelatin	Nil	72.5	Nil	Nil	72.5
Acacia	Nil	Nil	72.5	Nil	Nil
NG	Nil	Nil	Nil	72.5	Nil
Mg. Stearate	7.3	7.3	7.3	7.3	7.3
Talc	0.7	0.7	0.7	0.7	0.7
Total	500.0	500.0	500.0	500.0	500.0

Characterization of HS Granules

The obtained dried HS granules were subjected to the following tests;

• Particle size analysis

The mean granule sizes (MGS) of each of the formulation were determined with the aid of laboratory sieves of various pore sizes (1000 µm to < 75 µm (Pan) arranged in descending order. Known weight of sample was placed in the topmost sieve, belt of the shaker properly engaged and the Endecott sieves shaker operated for 10 minutes. Fraction of sample retained on each sieve was collected and weighed, [33].

The MGS values were calculated using Eq.1

$$\text{Mean granule size} = [\Sigma (\% \text{ retained}) \times (\text{sieve size})] / 100 \dots \dots \dots \text{Eq1}$$

• Moisture content analysis

The moisture content was determined using protocol described by Crouter and Brien 2013, [34]. Known weight of the sample was placed in a humidity chamber. The sample was re-weighed after operating the chamber for 48 hours. The weight gain/loss was determined as in Eq2.

$$MC = \left[\frac{W_1 - W_2}{W_1} \right] \times 100 \dots \dots \dots \text{Eq2}$$

• Angle of repose

This was determined using a powder flowability tester, (HMKFLOW 329, Dandong, HMKTEST Instrument Co. Ltd, China.). A known weight of granules was allowed to flow through the orifice of the instrument funnel fixed at an angle and height of about 45 ° and 8 cm respectively. The dimensions of height and radius of conical heap of powder formed were noted. The angle of repose was computed using Eq3, [33].

$$\tan \theta = \text{height of cone} / 0.5 \times \text{diameter} \dots\dots\dots \text{Eq3.}$$

• True, Bulk and Tapped densities

The loose volume (V_b) of a known weight (30g) of sample was noted in a measuring cylinder, while V_t was the volume of the same sample after 100 tapping of the measuring cylinder affording the sample particle rearrangement and realignment. The bulk (BD) and tapped TD) densities as well as other flow characteristics such as compressibility index (CI) and Hausner ratio(HR) of the samples were obtained using the expression in Eq 4-8. The true of densities (ρ_T) of the samples were determined using the pycnometric technique with n- Hexane as displacement fluid and 4g of sample.

$$\rho_T = 4g \times 0.661 / \text{Weight of displaced n - Hexane} \dots\dots\dots \text{Eq 4.}$$

Where ρ_T is the true density of sample and 0.661 is the density of n-Hexane

$$BD = 30g / V_b \dots\dots\dots \text{Eq5.}$$

$$TD = 30g / V_t \dots\dots\dots \text{Eq6.}$$

$$HR = V_b / V_t \dots\dots\dots \text{Eq7.}$$

$$CI = 100 \times \frac{V_b - V_t}{V_b} \dots\dots\dots \text{Eq8.}$$

• Compaction studies on HS granules

Tablets weighing 500mg were produced using a Carver hydraulic press (model C, Carver inc. Menomonee Falls, WI) fitted with 12.5mm die and flat faced punches lubricated with a 1% dispersion of Magnesium Stearate in acetone before each compression. A total of twenty five (25) tablets were produced per formulation at varying pressure, (50,100,150,200 and 250 MPa), [35, 36]. All tablets were properly label and kept in a desiccator charged with silica gel for 24 h to allow for elastic recovery. And for each of the formulation the mean of tablet weight, diameter and thickness after three reading were noted. The compacts were evaluated using Heckel and Kawakita equations, [37, 38, 39]

$$\ln (1/(1-D)) = KP + A \dots\dots\dots \text{Eq 9 (Heckel)}$$

Where D is the relative density of the sample (calculated using Eq 9), K is constant (relating the plasticity of the sample), P is the applied pressure and A is related to the die filling and particle rearrangement before deformation and bonding of the discrete particles obtained from the intercept of Heckel plot on y-axis.

$$D = \text{weight} / \text{Volume} \times \rho_T \dots\dots\dots \text{Eq 10}$$

$$\frac{P}{C} = \frac{P}{a} + \frac{1}{ab} \dots\dots\dots \text{Eq11 (Kawakita)}$$

The values of P represents the applied pressure, C is the degree of volume reduction, a & b are constants relating to the total degree of powder volume reduction and the yield strength of particles, respectively.

Tablet production and tableting properties of HS

Using a single punch tableting machine, (Type EKO, Erweka, Apparatebau-GmbH,

Germany) , HS tablets were produced as per the batch formulary (table 1). The tablets were properly labeled and kept in a desiccator for about 24 h for elastic recovery. The mean tablet weight, diameter and thickness were determined using digital weighing balance (EX 224, Ohaus, Switzerland) and a digital vernier caliper (model 500 Copley Scientific Nottingham UK). The properties of the resulting tablets were determined through the various tests prescribed by United States Pharmacopeia convention (USP2012).

Tablet production and tableting properties of HS

Using a single punch tableting machine, (Type EKO, Erweka, Apparatebau-GmbH,

Germany) , HS tablets were produced as per the batch formulary (table 1). The tablets were properly labeled and kept in a desiccator for about 24 h for elastic recovery. The mean tablet weight, diameter and thickness were determined using digital weighing balance (EX 224, Ohaus, Switzerland) and a digital vernier caliper (model 500 Copley Scientific Nottingham UK). The properties of the resulting tablets were determined through the various tests prescribed by United States Pharmacopeia convention (USP2012).

• Tablet crushing strength

The force required to diametrically break ten tablets from each batch were noted using a digital tablet hardness tester (porTAB 01, ToroTech, Canada). The mean of three determinations was recorded and taken as tablet crushing strength for the batch.

• Tablet weight lost

The weight lost recorded by twenty representative sample randomly picked per formulation using a Roche Friabilator, (Erweka TAR120, GmbH, Heusenstamm, Germany) operated at 25rpm for 4 min. The weight lost for each batch due to abrasion were computed and expressed as percentage of the initial weight of tablets, (Eq12)

$$F = \text{weight lost} / \text{Initial weight} \times 100 \dots\dots\dots \text{Eq12}$$

• Tablet disintegration time test

This was conducted us a BP disintegrating apparatus (model BJ-3, Ningbo Hinotek Instrument Co., Ltd, China). The mean time for six tablets placed in disintegrating basket to break into pieces and passed through the screen mesh at the bottom of the

basket was noted for each formulation. The temperature of the deionized water used as the disintegrating medium was maintained 37 °C and all other experimental conditions were as prescribed by USP 2020 [40].

Statistical analysis

The observed differences in both the compaction behavior and the tableting properties among the different formulations were subjected to statistical analysis (ANOVA) using the student's *t*-test as a statistical tool. A 95% confidence interval ($p \leq 0.05$) was considered significant.

RESULTS AND DISCUSSION

Table2: HS granules characterizations

Granules Character istics	HS1	HS2	HS3	HS4	HS5
Angle of repose(°)	48.82±0.13	29.1±0.02	30.6±0.03	31.6±0.06	31.8±0.06
True density (g/mL)	1.71±0.11	1.89±0.01	1.85±0.18	1.75±0.16	1.78±0.19
Bulk density (g/mL)	0.83±0.09	0.79±0.15	0.75±0.11	0.68±0.08	0.66±0.07
Tapped density (g/mL)	1.91±0.11	0.98±0.09	0.98±0.15	0.99±0.05	1.05±0.10
MGS (µm)	500.89±1.29	428±0.27	430.6±0.29	465±0.77	481±1.87
MC (%)	0.31±1.1	0.11±0.09	0.14±0.19	0.20±0.08	0.22±0.18
HR	2.3±0.01	1.24±0.09	1.31±0.16	1.46±0.05	1.59±0.05
CI (%)	56.5±0.14	19.4±0.06	23.5±0.16	31.3±0.11	37.1±0.24

The MGS and MC values differ from batch to batch and were ranged 428 -500 (µm) and 0.11- 0.31(%) respectively. These differences were significant, ($p \leq 0.05$) even though they were similarly ranked $HS1 \geq HS5 \geq HS4 \geq HS3 \geq HS2$. Both MGS and MC values are dependent on the nature of the different polymeric material used as diluents and binder in the formulations, [41,42]. Careful selection of materials is therefore advocated. There were significant differences ($p \leq 0.05$) in the values of the true, bulk and tapped densities, (table 2). While the true density of a material is the density of the material without void, which go a long way to influence critical unit operations such mixing, granulation process, compression and compactability of granules [39], the bulk and tapped densities however control both the fluidity and the flow of granules during tablet compression and as such optimization of the

granulation process is critical to achieving compacts of desire quality attributes [43, 44].

During tableting operations, the granules are expected to flow freely from the hopper into the die cavity to guaranty uniformity of tablets weight, diameter and thickness. The flow of granules represent a critical parameter that must be control in order to produce tablets of uniform micrometrics as well as to prevent dose variation that may lead to drug therapy failure. The angle of repose is use to assess the ability of materials to flow freely and uniformly under gravity from the hopper to the die wall during tablet manufacturing process. Materials with angle of repose values below 25 are classified as excellent, values ranging from 26 to 40 are moderate, while values above 40 are generally poor flowing material requiring addition of flow imparting substances (glidants). The values of the angle of repose obtained differ significantly ($p \leq 0.05$), from batch to batch and are ranked $HS2 \leq HS3 \leq HS4 \leq HS5 \leq HS1$.

The ranking order for ϕ above was basically the same for HR and CI.

CI is a measurement of material resistance to flow. [45, 46, 47]. Generally materials with high CI values have poor flow characteristics since they easily bond together as a result of high cohesive forces in play within the powder bed. HS1 had the highest values for CI, ϕ and HR (table 2) indicating extremely poor flowing granules and may not be suitable for compression on a rotary press. There is therefore the need to consistently strike a balance between powder cohesiveness and the flow. [48, 49]

Table3: Tableting properties of HS

Parameter s	HS1	HS2	HS3	HS4	HS5
Av.Tab. Weight (g)	0.5±0.07	0.5±0.27	0.49±0.32	0.49±0.32	0.49±0.38
Friability (%)	≥ 1.00	0.20±0.32	0.22±0.22	0.34±0.32	0.34±0.38
Crushing strength (KgF)	4.5±2.05	5.5±0.32	5.5±0.32	4.5±2.05	4.5±2.05
Disintegr ation time test (Min)	9.4±2.35	6.0±1.32	6.0±1.32	6.6±1.32	6.6±1.32

There were significant batch to batch variations ($p \leq 0.05$) among HS tablets produced. (Table 3). The mean tablet weights and the crushing strengths ranged from 0.49±0.32 to 0.5±0.07 and 4.5±2.05 to 5.5±0.32 indicating total compliance with the official (USP 2012) specifications for tablet weight uniformity and tablets hardness, which guaranty both dose uniformity and resistance to breakage during transportation and handling.

However, HS1 tablets were highly friable even though it passed the official test for tablet hardness. This poor friability may be as

result of high MGS values which present less contact and bonding force within tablets [50]. All the batches of HS formulations investigated in this study passed the disintegration time test as the mean disintegration time test were all below 15 minutes. The differences observed for disintegration time test were significant ($P \leq 0.05$) and may not be unconnected with differences in the intrinsic properties of the polymeric materials employed as excipients in the batch formulary. [51]

Table 4: Heckel and Kawakita Compaction properties of HS granules

Formulations	Py (Mpa)	Heckel			Kawakita		
		DA	DO	DB	a	b	PK
HS1	66.47	0.75	0.49	0.26	03.00	0.2500	4.00
HS2	166.7	0.86	0.41	0.45	22.00	0.0227	44.05
HS3	800.00	0.80	0.41	0.39	18.00	0.0277	36.10
HS4	210.53	0.83	0.39	0.44	38.00	0.0132	75.00
HS5	400.00	0.94	0.37	0.57	35.00	0.0143	69.93

The compaction parameters, (compactability) of HS granules were assessed through the Heckel and Kawakita plots, (Figure 1 & 2).

While Heckel plot relates the HS granules relative density, (natural log) to the compaction pressure, Kawakita plot expressed the degree of volume reduction of HS granule to the compaction pressure.

All HS formulations under investigation were compactable, but with different significant ($p \leq 0.05$) degree of compactability under applied pressure, (table 4).

Individual onsets of plastic deformation (Py) of HS formulations were obtained from the inverse proportion of the slope of Heckel plots and were ranked $HS1 \leq HS2 \leq HS4 \leq HS5 \leq HS3$. (table 4).

High value of Py means that it take longer time for the material to deformed plastically which is an undesirable situation in tablet manufacturing processes since the resident time of the granules to form compacts in the rotary press are low.




Figure 1: Heckel plot for 5 batches of HS granules




Figure2: Kawakita Plot

And as such a judicious selection of both the excipient and the granulation conditions is advocated. The degree of densification at the initial phase of compaction (DA) were obtained mathematically and were ranked, $HS5 \geq HS2 \geq HS4 \geq HS3 \geq HS1$. The low initial densification of HS1 may be connected to its lack of binder, revealing the important of binding agent in tablet formulation. The trend/order of consolidation due to particle in motion i.e. rearrangement at the initial stage DO and that due to fragmentation DB remain unchanged, (table 4).

The obtained data were equally fitted to Kawakita model with 0.99 correlations. All HS granules underwent volume reduction under compaction pressure to various degrees of densification (Figure2). The linear relationship between volume reduction and compaction pressure makes it possible to derive values for three key parameters, a, the minimum granules porosity just before compaction and its equal the y- axis intercept. The parameter b is a good measure of material plasticity and its reciprocal (PK) is the pressure that cause volume reduction by one-half (50%). The differences in the values of a and b are significant ($p < 0.05$) showing the effects of diluents and binders on the compaction behavior of HS granules. There is therefore the need for optimization and quantification of the formulations. The PK values ranged from 4.00 to 75.00 and were ranked $HS1 \leq HS3 \leq HS2 \leq HS5 \leq HS4$. There is a direct

proportionality between PK values and the total plasticity of a material, therefore formulation HS1 underwent the least plastic deformation while HS4 had highest plastic deformation. The differences observed among the HS formulations may not be unconnected with different binders and diluents used and therefore there is a need to optimize the formulations through a critical evaluation of the contributing effects of nature and the concentration of various excipients on the compression and compaction of HS formulations.

CONCLUSION

HS aqueous extract was successful formulated into oral tablets which will ensure accurate dosing and ease its administration as adjuvant in the management of essential hypertension. Among the five formulations investigated in this study, only one of the formulations (HS1) failed the friability test conducted according to USP 2012 even though its onset of plastic deformation was the quickest judging by its least value of the obtained mean yield pressure. HS1 gave the lowest value for plastic deformation (PK) which may responsible for its failure of friability test and the fact that the formulation lack binder showing the critical role of binder in tablet formulations.

REFERENCES

1. Tsai PJ, McIntosh J, Pearce P, Camden B. "Anthocyanin and antioxidant capacity in Roselle (*Hibiscus sabdariffa* L.) extract," *Food Res Int.*, 2002; 35: 351-356.
2. Ademiluyi AO, Oboh -Agbebi GOJ, Akinyemi AJ "Anthocyanin-rich red dye of *Hibiscus sabdariffa* calyx modulates Cisplatin-induced nephrotoxicity and oxidative stress in rats," *Int J Biomed Sci*, 2013; 9: 243-248.
3. Aliyu B, Oyeniya YJ, Mojiminiyi FBO, Isezuo SA, Alada ARA. The aqueous calyx extract of *Hibiscus Sabdariffa* lowers blood pressure and heart rate via sympathetic nervous system dependent mechanisms. *Nigeria Journal of physiological sciences*, 2014; 29: 131-136.
4. Islam MM, Food and Medicinal Values of Roselle (*Hibiscus sabdariffa* L. Linne Malvaceae) Plant Parts. *Open J Nutr Food Sci.* 2019; 1: 1003-1006
5. Tsai PJ, McIntosh-Pearce JP, Camden B et al. "Anthocyanin and antioxidant capacity in Roselle (*Hibiscus sabdariffa* L.) Extract," *Food Res Int* 2002; 35: 351-356.
6. Mojiminiyi FBO, Dikko M, Muhammad BY, Ojobor PD. Antihypertensive effect of an aqueous extract of the calyx of *Hibiscus sabdariffa*. *Fitoterapia*. 2007; 78: 292-297.
7. Haji-Faraji M, Haji-Tarkhani A. The effect of sour tea (*Hibiscus sabdariffa*) on essential hypertension. *J. Ethnopharmacol.* 1999; 65:231-236.
8. Odigie IP, Ettarh RR, Adigun SA. Chronic administration of aqueous extract of *Hibiscus sabdariffa* attenuate hypertension and reverses cardiac hypertrophy in 2K-1 hypertensive rats. *J. Ethnopharmacol.* 2003; 86:181-185
9. Mohd-Esa N, Hern FS, Ismail, A, Yee C.L "Antioxidant activity in different parts of roselle (*Hibiscus sabdariffa* L.) Extracts and potential exploitation of the seeds," *Food Chemistry*. 2010; 122: 1055-1060.
10. Hirunpanich V, Utaipat A, Morales NP et al. "Hypocholesterolemic and antioxidant effects of aqueous extracts from the dried calyx of *Hibiscus sabdariffa* L. in hypercholesterolemic rats," *J Ethnopharmacology*. 2006; 103: 252-260.

11. Gurrola-Díaz CM, García-López, PM, Sánchez-Enríquez S. "Effects of Hibiscus sabdariffa extract powder and preventive treatment (diet) on the lipid profiles of patients with metabolic syndrome (MeSy)," *Phytomedicine*. 2010; 17: 500-505.
12. Alarcon-Aguilar FJ, Zamilpa A, Perez-Garcia MD. "Effect of Hibiscus sabdariffa on obesity in MSG mice," *J. Ethnopharmacology*. 2007; 114: 66-71.
13. Tseng TH, Kao ES, Chu CY. "Protective effects of dried flower extracts of Hibiscus sabdariffa L. against oxidative stress in rat primary hepatocytes," *Food and Chemical Toxicology*. 1997; 35: 1159-1164.
14. Alarcón-Alonso J, Zamilpa A, Aguilar FAM. "Pharmacological characterization of the diuretic effect of Hibiscus sabdariffa Linn (Malvaceae) extract," *J. Ethnopharmacology*. 2012; 139: 751-756.
15. Al-Mamun M, Khatun H, Nesa ML "In vitro evaluation of the antibacterial, cytotoxic and insecticidal activities of Hibiscus Sabdariffa fruits," *Libyan Agriculture Research Center Journal International*. 2011; 2: 144-149.
16. Abou-Arab AA, Abu-salem FM, Abou-Arab EM, Physico-chemical properties of natural pigments (anthocyanin) extracted from Roselle calyces (Hibiscus sabdariffa), *J. Am. Sci*. 2011; (7): 445-456.
17. Sinela A, Rawat N, Mertz C. Anthocyanins degradation during storage of Hibiscus Sabdariffa extract and evolution of its degradation products. *Food Chem*. 2017; (214):234-241.
18. Ramirez-Rodrigues MM, Balaban MO, Marshall MR, 2011. Hot and cold water infusion aroma profiles of Hibiscus sabdariffa: fresh compared with dried. *J. Food Science*. 2011; (76): 212-217.
19. Ramirez-Rodrigues MM, Plaza ML, Azeredo A. et al. Physicochemical and phytochemical properties of cold and hot water extraction from Hibiscus sabdariffa. *Journal of Food Science*. 2011; (76):428-435
20. Bako PM, Hypotensive effect of aqueous seed extract of Hibiscus sabdariffa linn (Malvaceae) on normotensive cat. *International J. of animal sciences and Veterinary advances*. 2010; 2: 5-8.
21. Ochani PC, Mello PD. Antioxidant and anti-hyperlipidemic activity of Hibiscus sabdariffa Linn, leaves and calyces extracts in rats. *Indian Journal of Experimental Biology*. 2009; 47:276-282.
22. McKay DL, Chen CYO, Saltzman E. et al. Hibiscus sabdariffa L. tea (tisane) lowers blood pressure in Pre-hypertensive and Mildly hypertensive adults. *J. Nutr*. 2010; (140): 298-303.
23. Herrera-Arellano A, Flores-Rameo S, Chavez-soto MA, et al. Effectiveness and tolerability of standardized extract from Hibiscus sabdariffa in patients with mild to moderate Hypertension. *Phytomedicine*. 2004; (11):375-382.
24. M Haji-Faraji and A Haji-Tarkhani The effect of sour tea (Hibiscus sabdariffa) on essential hypertension. *J. Ethanopharmacol.*, 65:231-236, 1999
25. Herrera-Arellano A, Miranda-Sanchez J, Avica-Castro P. Clinical effects produced by a standardized herbal medicinal product of Hibiscus sabdariffa on patients with hypertension. A randomized, double-blind, lisinopril-controlled clinical trial. *Planta Medica*. 2007; 73:6-12.
26. Aliyu B, Oyeniyi YJ, Mojiminiyi FBO, et al. The Aqueous Calyx Extract of Hibiscus sabdariffa Lowers Blood Pressure and Heart Rate via Sympathetic Nervous System Dependent Mechanisms. *Niger. J. Physiol. Sci*. 2014; (29): 131-136.
27. Hopkins AL, Lamm, MG, Funk JL. Hibiscus sabdariffa L. in the treatment of hypertension and hyperlipidemia: a comprehensive review of animal and human studies. *Fitoterapia*. 2013; (85):84-94.
28. Kunle OO, Nasipuri RN, Wambebe CN. Effect of some surfactants on the properties of Granules and Tablets of the Hot Water Leaf extract of Ficus Sur. *West African Journal of Pharmacy*. 2001; (15): 35-42.
29. Kunle OO. Formulation studies on the hot water leaf extract of F. sur (Moraceae): Effect of insoluble diluents on compact characteristics. *Nig. J. Pharm*. 2002; (33): 35-41.
30. Osamura T, Takeuchi Y, Onodera R, et al. Formulation design of granules prepared by wet granulation method using a multi-functional single-punch tablet press to avoid tableting failures, *Asian J. of Pharma. Sci*. 2017; (13):113-119.
31. Roberts M, Ford JM, Macleod GS. Effect of punch tip geometry and embossment on the punch tip adherence of a model ibuprofen formulation. *J of Pharm. and Pharmacol*. 2004; 56: 947-950.
32. Sandler N, Reiche K, Heinamaki J. Effect of moisture on powder flow properties of theophylline. *Pharmaceutics*. 2010; 2:275-90.
33. United States Pharmacopoeia (USP). The United States Pharmacopoeial Convention, Rockville, Maryland 2012
34. Crouter A, Briens L. The effect of moisture on the flowability of pharmaceutical excipients. *AAPS PharmSciTech*, 2014; 15:65-74
35. Alebiowu G. Studies on the tableting properties of Sorghum Bicolor Linn (Poaceae) starch I: Evaluation of binder types and concentrations on the properties of sorghum starch granulations. *Discov Innov*. 2001; (13): 73-77.
36. Fell J, Newton J (1970) Determination of tablet strength by the diametral compression test. *J Pharm Sci*; 59:688-691
37. Heckel RW. Density-pressure relationships in powder compaction. *Trans Metall Soc AIME*. 1961; 221:671-675
38. Kawakita K, Lüdde KH . Some considerations on powder compression equations. *Powder Technol*. 1971; 4:61-68
39. Szumilo M, Belniak P, Swiader K, Holody E, Poleszak E. Assessment of physical properties of granules with paracetamol and caffeine. *Saudi Pharm J*. 2017; 25: 900-905
40. United States Pharmacopoeia (USP). The United States Pharmacopoeial Convention, Rockville, Maryland 2020
41. Oyeniyi YJ, Yusuf AJ (2019). Quantitative effects of formulation process variables on antitumor activities of doxorubicin nanoparticles. *Braz. J. Technol., Curitiba*. 2019; (2): 967-983
42. Oyeniyi YJ, Yusuf AJ. The effects of process variables on physicochemical properties and in-vitro cytotoxic activities of 5 fluorouracil nanoparticles against squamous cell carcinoma (SCC). *West African Journal of Pharmacy*. 2020; (31):45 - 52
43. Riley CK, Adebayo SA. A comparative investigation of the packing and flow properties of sweet potato (Ipomea batatas) starches and their potential uses in solid dosage formulations, *Starch-Starke*. 2010; (62): 285-293.
44. Wünscher I, Finke JH, John E, et al. A mathematical approach to consider solid compressibility in the compression of pharmaceutical powders *Pharmaceutics*. 2019; 11:1-19.
45. Chinwan D, Chinwan ME. Effect of conditioner and moisture content on flowability of yellow cornmeal. *Food Sci Nutr*. 2019; (7): 3261-3272
46. Sandler N, Wilson D. Prediction of granule packing and flow behavior based on particle size and shape analysis. *J. Pharm. Sci*. 2010; (99): 958-968.
47. Schulze D. Flow properties of bulk solids. In *Powders and bulk solids: Behavior, characterization, storage and flow*. Springer, Berlin, Heidelberg. 2008; 35-74.
48. Ayorinde JO, Odeniyi MA, Oyeniyi YJ. Material and compression properties of native and modified plantain starches. *Farmacia*. 2013; (61): 574-590
49. Odeniyi MA, Abobarin TO, Itiola OA. Compressibility and flow characteristics of binary mixtures of metronidazole with lactose and microcrystalline cellulose, *Farmacia*. 2008; (5): 625-638.

50. Odeku OA, Itiola OA. Effects of interacting variables on the tensile strength and the release properties of paracetamol tablets. Trop J Pharm Res. 2003; (2):147-153.
51. Akin-Ajani OD, Itiola OA, Odeku OA. (2005). Effects of plantain and corn starches on the mechanical and disintegration properties of paracetamol tablets AAPS PharmSciTech. 2003; 6:E458-63